Connor, Clark & Lunn Investment Management Ltd. Eton Pharmaceuticals, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $18.8 Billion
- Q3 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Eton Pharmaceuticals, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 65,014 shares of ETON stock, worth $828,278. This represents 0.0% of its overall portfolio holdings.
Number of Shares
65,014
Previous 34,847
86.57%
Holding current value
$828,278
Previous $114,000
242.11%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ETON
# of Institutions
51Shares Held
9.44MCall Options Held
261KPut Options Held
500-
Opaleye Management Inc. Boston, MA2.78MShares$35.4 Million3.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.03MShares$13.1 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT999KShares$12.7 Million0.36% of portfolio
-
Westside Investment Management, Inc.619KShares$7.88 Million0.79% of portfolio
-
Acuitas Investments, LLC580KShares$7.39 Million1.66% of portfolio
About Eton Pharmaceuticals, Inc.
- Ticker ETON
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,297,000
- Market Cap $322M
- Description
- Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for th...